ENCell Co., Ltd. (KOSDAQ:456070)

South Korea flag South Korea · Delayed Price · Currency is KRW
16,280
-180 (-1.09%)
Apr 29, 2026, 3:30 PM KST
14.25%
Market Cap 181.08B
Revenue (ttm) 5.26B
Net Income (ttm) -16.11B
Shares Out 11.00M
EPS (ttm) -1,482.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 70,161
Average Volume 104,847
Open 16,450
Previous Close 16,460
Day's Range 16,100 - 16,650
52-Week Range 10,000 - 20,950
Beta n/a
RSI 57.40
Earnings Date n/a

About ENCell

ENCell Co., Ltd. develops cell/gene-based biopharmaceutical products in South Korea. The company develops EN00, an allogeneic umbilical cord-derived mesenchymal stem cell treatment for Charcot-Marie-Tooth disease. It also provides contracting development and manufacturing services for biopharmaceutical products. The company was founded in 2018 and is based in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 456070
Full Company Profile

Financial Performance

In 2025, ENCell's revenue was 5.26 billion, a decrease of -27.06% compared to the previous year's 7.21 billion. Losses were -16.11 billion, 5.90% more than in 2024.

Financial Statements

News

There is no news available yet.